When is TARS's latest earnings report released?
The most recent financial report for Tarsus pharmaceuticals, inc. (TARS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TARS's short-term business performance and financial health. For the latest updates on TARS's earnings releases, visit this page regularly.
What is the operating profit of TARS?
According to the latest financial report, Tarsus pharmaceuticals, inc. (TARS) reported an Operating Profit of -7.98M with an Operating Margin of -5.26% this period, representing a growth of 67.34% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is TARS's revenue growth?
In the latest financial report, Tarsus pharmaceuticals, inc. (TARS) announced revenue of 151.67M, with a Year-Over-Year growth rate of 128.39%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does TARS have?
At the end of the period, Tarsus pharmaceuticals, inc. (TARS) held Total Cash and Cash Equivalents of 184.2M, accounting for 0.33 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does TARS go with three margins increasing?
In the latest report, Tarsus pharmaceuticals, inc. (TARS) did not achieve the “three margins increasing” benchmark, with a gross margin of 92.8%%, operating margin of -5.26%%, and net margin of -5.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TARS's profit trajectory and future growth potential.
Is TARS's EPS continuing to grow?
According to the past four quarterly reports, Tarsus pharmaceuticals, inc. (TARS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.19. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TARS?
Tarsus pharmaceuticals, inc. (TARS)'s Free Cash Flow (FCF) for the period is 12.97M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 147.6% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TARS?
The latest valuation data shows Tarsus pharmaceuticals, inc. (TARS) has a Price-To-Earnings (PE) ratio of -44.59 and a Price/Earnings-To-Growth (PEG) ratio of 3.14. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
